Evidence map›Paper›PMID 36230843›Full record

ReviewCancers2022

Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier.

Andrew M Hersh, Meghana Bhimreddy, Carly Weber-Levine, Kelly Jiang, Safwan Alomari, Nicholas Theodore, Amir Manbachi, Betty M Tyler

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Andrew M HershDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-1755-3974
Meghana BhimreddyDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-7570-4094
Carly Weber-LevineDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-2057-8419
Kelly JiangDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-1144-7882
Safwan AlomariDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-7595-818X
Nicholas TheodoreDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Amir ManbachiDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-0206-5230
Betty M TylerDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-9800-6969
Johns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is an aggressive primary astrocytoma associated with short overall survival. Treatment for GBM primarily consists of maximal safe surgical resection, radiation therapy, and chemotherapy using temozolomide. Nonetheless, recurrence and tumor progression is the norm, driven by tumor stem cell activity and a high mutational burden. Focused ultrasound (FUS) has shown promising results in preclinical and clinical trials for treatment of GBM and has received regulatory approval for the treatment of other neoplasms. Here, we review the range of applications for FUS in the treatment of GBM, which depend on parameters, including frequency, power, pulse duration, and duty cycle. Low-intensity FUS can be used to transiently open the blood-brain barrier (BBB), which restricts diffusion of most macromolecules and therapeutic agents into the brain. Under guidance from magnetic resonance imaging, the BBB can be targeted in a precise location to permit diffusion of molecules only at the vicinity of the tumor, preventing side effects to healthy tissue. BBB opening can also be used to improve detection of cell-free tumor DNA with liquid biopsies, allowing non-invasive diagnosis and identification of molecular mutations. High-intensity FUS can cause tumor ablation via a hyperthermic effect. Additionally, FUS can stimulate immunological attack of tumor cells, can activate sonosensitizers to exert cytotoxic effects on tumor tissue, and can sensitize tumors to radiation therapy. Finally, another mechanism under investigation, known as histotripsy, produces tumor ablation via acoustic cavitation rather than thermal effects.

Indexed as

blood–brain barrierfocused ultrasoundFUSglioblastomatargeted therapy

Identifiers

PMID36230843
PMCPMC9563027
OpenAlexW4303685466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.